Neurocrine Biosciences Overview
Neurocrine Biosciences Target Price
See Neurocrine Biosciences's analyst price targets ($200) vs the current share price.
Get informed when a big investor buys or sells
+ FollowShare Price
$157.22
Average Target Price
$200.17
27.3% upside
27.3% upside23 analysts in the last 4 months
High: $225 | Low: $165
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-09-11 | Morgan Stanley | $183 | 16.4% upside |  |
| 2026-09-08 | RBC CapitalBrian Abrahams | $198 | 25.9% upside | |
| 2026-08-13 | Bernstein | $218 | 38.7% upside | |
| 2026-08-13 | Morgan Stanley | $182 | 15.8% upside | |
| 2026-08-13 | Deutsche Bank | $165 | 4.9% upside | |
| 2026-08-03 | Wedbush | $194 | 23.4% upside | |
| 2026-08-03 | H.C. WainwrightAndrew Fein | $215 | 36.8% upside | |
| 2026-08-03 | Canaccord GenuitySumant Kulkarni | $210 | 33.6% upside | |
| 2026-07-31 | Morgan Stanley | $196 | 24.7% upside | |
| 2026-07-31 | Deutsche BankDavid Hoang | $190 | 20.8% upside | |
| 2026-07-31 | Needham | $204 | 29.8% upside | |
| 2026-07-31 | Piper SandlerGAAP EPS | $210 | 33.6% upside | |
| 2026-07-31 | Robert W. BairdBrian Skorney | $225 | 43.1% upside | |
| 2026-07-31 | Guggenheim | $222 | 41.2% upside | |
| 2026-07-21 | Guggenheim | $200 | 27.2% upside | |
| 2026-07-17 | Wells Fargo | $200 | 27.2% upside | |
| 2026-07-13 | Truist Financial | $200 | 27.2% upside | |
| 2026-07-13 | BMO Capital | $170 | 8.1% upside | |
| 2026-07-13 | Wedbush | $185 | 17.7% upside | |
| 2026-07-07 | RBC CapitalBrian Abrahams | $195 | 24% upside | |
| 2026-06-30 | UBS | $208 | 32.3% upside | |
| 2026-06-02 | Goldman SachsCorinne Johnson | $213 | 35.5% upside | |
| 2026-05-21 | BernsteinJeffrey Walch | $221 | 40.6% upside | |
| 2026-05-06 | Oppenheimer | $230 | 46.3% upside | |
| 2026-05-06 | Piper Sandler | $207 | 31.7% upside | |
| 2026-04-06 | Oppenheimer | $220 | 39.9% upside | |
| 2026-03-10 | Cantor FitzgeraldJosh Schimmer | $195 | 24% upside | |
| 2026-02-23 | Wolfe Research | $160 | 1.8% upside | |
| 2026-02-17 | Truist FinancialDanielle Brill | $140 |  11% downside | |
| 2026-02-12 | Needham | $185 | 17.7% upside | |
| 2026-02-12 | RBC Capital | $177 | 12.6% upside | |
| 2026-02-12 | Wedbush | $151 | 4% downside | |
| 2026-02-12 | Morgan Stanley | $173 | 10% upside | |
| 2026-02-12 | H.C. Wainwright | $192 | 22.1% upside | |
| 2026-01-23 | UBS | $178 | 13.2% upside | |
| 2026-01-08 | Truist Financial | $169 | 7.5% upside | |
| 2026-01-08 | Morgan Stanley | $175 | 11.3% upside | |
| 2026-01-05 | UBSAshwani Verma | $188 | 19.6% upside | |
| 2025-12-17 | H.C. Wainwright | $198 | 25.9% upside | |
| 2025-12-11 | Stifel Nicolaus | $188 | 19.6% upside | |
| 2025-12-08 | RBC Capital | $180 | 14.5% upside | |
| 2025-10-29 | Truist FinancialDanielle Brill | $172 | 9.4% upside | |
| 2025-10-29 | UBS | $183 | 16.4% upside | |
| 2025-10-29 | RBC Capital | $160 | 1.8% upside | |
| 2025-10-29 | Mizuho Securities | $146 | 7.1% downside | |
| 2025-10-29 | Stifel NicolausPaul Matteis | $183 | 16.4% upside | |
| 2025-10-29 | BMO Capital | $147 | 6.5% downside | |
| 2025-10-29 | NeedhamAmi Fadia | $184 | 17% upside | |
| 2025-10-29 | Piper Sandler | $179 | 13.9% upside | |
| 2025-10-29 | JefferiesAkash Tewari | $174 | 10.7% upside | |